

CITATION REPORT

List of articles citing

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine

DOI: 10.1038/clpt.1991.4

Clinical Pharmacology and Therapeutics, 1991, 49, 18-23.

Source: <https://exaly.com/paper-pdf/22362947/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
128	The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. <i>British Journal of Clinical Pharmacology</i> , 1991 , 31, 689-92	3.8	120
127	Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 49, 624-31	6.1	14
126	Genetically Determined Polymorphisms in Drug Metabolism. 1992 , 5, 317-336		
125	Pharmacogenetics: Part II. 1992 , 26, 255-61		7
124	Inhibitors of imipramine metabolism by human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 1992 , 34, 256-61	3.8	126
123	The role of individual human cytochromes P450 in drug metabolism and clinical response. 1992 , 13, 434-9		202
122	Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. <i>European Journal of Clinical Pharmacology</i> , 1992 , 43, 405-11	2.8	42
121	High-performance liquid chromatography of imipramine and six metabolites in human plasma and urine. 1993 , 612, 87-94		23
120	The pharmacogenetics of the selective serotonin reuptake inhibitors. 1993 , 71, 1002-9		59
119	Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. <i>European Journal of Clinical Pharmacology</i> , 1993 , 44, 403-5	2.8	29
118	Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. <i>Clinical Pharmacology and Therapeutics</i> , 1993 , 53, 89-95	6.1	34
117	Metabolic polymorphisms. 1993 , 57, 129-60		159
116	Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations. <i>European Journal of Clinical Pharmacology</i> , 1993 , 44, 593-5	2.8	16
115	Fluvoxamine is a potent inhibitor of cytochrome P4501A2. 1993 , 45, 1211-4		321
114	Molecular basis of drug oxidation polymorphisms. 1993 , 47, 27-31		
113	Risk factors in elderly taking psychotropic drugs: Significance of genetic polymorphism in drug oxidation. 1993 , 47, 85-89		4
112	Genetically determined adverse drug reactions involving metabolism. 1993 , 9, 60-77		27

111	Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications. 1993 , 24, 141-60		35
110	Pharmacogenetics of Agents Acting on the Central Nervous System. 1993 , 6, 2-16		2
109	The effect of moderate hemodilution with Fluosol on cytochrome P4502D6 activity in the rat. 1994 , 22, 1237-42		
108	Determination of the enantiomers of mianserin, desmethylmianserin, and 8-hydroxymianserin in the plasma and urine of mianserin-treated patients. 1994 , 6, 555-63		19
107	Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. 1994 , 31, 177-86		56
106	Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications. 1994 , 29, 121-37		12
105	Clinical pharmacokinetics of fluvoxamine. 1994 , 27, 175-90		56
104	Pharmacokinetics of Drugs. <i>Handbook of Experimental Pharmacology</i> , 1994 ,	3.2	1
103	The role of S-mephenytoin 4Hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. <i>British Journal of Clinical Pharmacology</i> , 1994 , 37, 237-42	3.8	33
102	Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 471-6	6.1	82
101	Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 176-83	6.1	51
100	Interethnic Factors Important for Drug Development and Registration. 1995 , 12, 23-46		1
99	Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 57, 670-7	6.1	97
98	Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 58, 404-11	6.1	114
97	Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. <i>British Journal of Clinical Pharmacology</i> , 1995 , 39, 433-9	3.8	39
96	The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4Hydroxylase activity in human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 1995 , 40, 481-5 ⁸		61
95	Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. 1995 , 29 Suppl 1, 10-8; discussion 18-9		104
94	Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. 1995 , 29 Suppl 1, 45-52		56

93	Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. 1995 , 29, 192-209		308
92	Paroxetine shifts imipramine metabolism. 1996 , 59, 189-96		45
91	Polymorphic Drug Oxidation. 1996 , 5, 200-223		94
90	Imipramine: a model drug for P450 research. 1996 , 272, 177-86		5
89	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. <i>European Journal of Clinical Pharmacology</i> , 1996 , 51, 73-8	2.8	261
88	Psychiatry, psychopharmacology and P-450s. 1996 , 11, 97-114		31
87	Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantioselective analytical methods. 1996 , 678, 73-92		14
86	Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 322-31	6.1	56
85	Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 647-53	6.1	101
84	Genotyping of S-mephenytoin 4Hydroxylation in an extended Japanese population. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 661-6	6.1	241
83	Drug Interactions Associated with Cytochrome P-450 Enzymes. 1996 , 4, 35-54		2
82	Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. 1996 , 29, 108-10		33
81	The Role of Metabolites of Antidepressants in the Treatment of Depression. 1997 , 7, 273-312		36
80	Drug interactions of clinical significance with selective serotonin reuptake inhibitors. 1997 , 17, 390-406		57
79	The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition. 1997 , 41, 814-26		32
78	Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. 1997 , 51, 253-7		28
77	Pharmacogenetics of antidepressants: clinical aspects. 1997 , 391, 14-21		66
76	Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. <i>European Journal of Clinical Pharmacology</i> , 1997 , 52, 129-33	2.8	64

75	Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 61, 319-24	6.1	23
74	Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 18-26	6.1	45
73	Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 391-401	6.1	76
72	Human cytochrome P450s: selectivity and measurement in vivo. 1998 , 28, 1095-128		95
71	The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. 1998 , 39, 1317-23		144
70	[Significance of hepatic cytochrome P450 enzymes for psychopharmacology]. 1998 , 69, 944-55		17
69	Pharmacogenetics of the hepatic cytochrome P450 enzyme system: its relevance for prescribing in psychiatry. 1998 , 15, 96-99		
68	Lipoxygenase-Mediated N-Demethylation of Imipramine and Related Tricyclic Antidepressants in the Presence of Hydrogen Peroxide. 1999 , 18, 251-257		4
67	Metabolism of tricyclic antidepressants. 1999 , 19, 373-409		158
66	Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. 1999 , 29, 59-124		234
65	Imipramine for Cytochrome P450 Activity Determination: a Multiple-species Metabolic Probe. 1999 , 13, 537-41		5
64	The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat. 1999 , 9, 337-44		13
63	Development of a semi-quantitative assay to detect full-length CYP2C19 RNA. 2000 , 29, 364-70, 372-3		4
62	The CYP2C19 enzyme polymorphism. 2000 , 61, 174-83		140
61	Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. 2000 , 1, 125-51		87
60	The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. 2000 , 16, 39-67		30
59	Effect of venlafaxine on imipramine metabolism. 2000 , 96, 235-43		33
58	Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. 2001 , 40, 753-72		98

57	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. 2001 , 104, 173-92		285
56	Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 349-55	3.8	450
55	Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 174-82	1.7	33
54	Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. 2002 , 12, 571-80		51
53	Clinical significance of the cytochrome P450 2C19 genetic polymorphism. 2002 , 41, 913-58		645
52	Clinical implications of CYP2C19 polymorphism for tailor-made pharmacotherapy. 2002 , 1244, 41-49		1
51	The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. <i>European Journal of Clinical Pharmacology</i> , 2002 , 58, 109-13	2.8	35
50	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. 2002 , 19, 1034-7		21
49	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. 2003 , 138, 1465-74		40
48	Clinical pharmacokinetics of drugs used to treat urge incontinence. 2003 , 42, 1243-85		91
47	Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. 2003 , 36 Suppl 3, S235-43		26
46	Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. 2004 , 9, 442-73		575
45	In vitro microsomal metabolism of imipramine under conditions mimicking the in vivo steady-state situation. 2004 , 19, 31-6		3
44	Some aspects of genetic polymorphism in the biotransformation of antidepressants. 2004 , 59, 5-12		65
43	Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s. 2005 , 205, 237-46		33
42	Pharmacogenetics of Antidepressant Drug Metabolism and Its Clinical Implications. 2005 , 879-902		
41	Psychopharmacogenetics. 2006 ,		5
40	Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. 2006 , 2, 875-94		948

39	Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation. 2006 , 51, 118-123		5
38	Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. 2006 , 58, 521-90		328
37	Pharmacogenetics: part II: Perspective. 1992. 2007 , 41, 2048-54		
36	Sex-specific differences in CYP450 isoforms in humans. 2008 , 4, 413-24		121
35	Drug-Drug Interactions, Second Edition. 2008 ,		6
34	Polymorphism of human cytochrome P450 enzymes and its clinical impact. 2009 , 41, 89-295		579
33	SNPs: Single Nucleotide Polymorphisms and Pharmacogenomics: Individually Designed Drug Therapy. 2010 , 181-204		
32	A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. 2010 , 45, 1045-52		14
31	Species Differences of Drug-Metabolizing Enzymes. 2012 , 1		1
30	Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. 2012 , 3, 318		38
29	Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. 2015 , 30, 147-63		3
28	The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine. <i>Drug Metabolism and Disposition</i> , 2016 , 44, 1569-78	4	17
27	Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 285-296	2.8	3
26	P450 Pharmacogenetics in Indigenous North American Populations. <i>Journal of Personalized Medicine</i> , 2018 , 8,	3.6	12
25	A Biological, Environmental, and Cultural Basis for Ethnic Differences in Treatment. 1996 , 389-406		2
24	Role of genetic polymorphism in psychopharmacology--an update. <i>Psychopharmacology Series</i> , 1993 , 10, 199-211		15
23	The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.. <i>Journal of Biological Chemistry</i> , 1994 , 269, 15419-15422	5-4	649
22	Interindividual variations of desmethylation and hydroxylation of amitriptyline in a Japanese psychiatric population. <i>Journal of Clinical Psychopharmacology</i> , 1995 , 15, 175-81	1.7	9

21	Tamoxifen-associated reduction in tricyclic antidepressant levels in blood. <i>Journal of Clinical Psychopharmacology</i> , 1995 , 15, 223-4	1.7	3
20	The emerging role of cytochrome P450 3A in psychopharmacology. <i>Journal of Clinical Psychopharmacology</i> , 1995 , 15, 387-98	1.7	122
19	Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 273-85	1.7	61
18	Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4-hydroxylation status in Japanese depressive patients. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 286-93	1.7	29
17	Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 345-55	1.7	59
16	Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. <i>Therapeutic Drug Monitoring</i> , 1996 , 18, 393-6	3.2	81
15	A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 1-6	3.2	13
14	Death of Two Subjects Due to Imipramine and Desipramine Metabolite Accumulation During Chronic Therapy: A Review of the Literature and Possible Mechanisms. <i>Journal of Forensic Sciences</i> , 1997 , 42, 1412-4J	1.8	2
13	SNPs: Single Nucleotide Polymorphisms and Pharmacogenomics Individually Designed Drug Therapy. 2003 , 607-639		1
12	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants. 2004 , 149-173		
11	Drug-Metabolizing Enzymes and P-Glycoprotein. 2004 , 43-67		
10	Drug-Metabolizing Enzymes. 2009 , 85-117		
9	Tricyclic Antidepressant Drug Interactions. 2012 , 193-214		
8	Phenotypes for psychotropic drug metabolism in the elderly. <i>Psychopharmacology Series</i> , 1993 , 10, 238-45		
7	Clinical Relevance of Pharmacogenetics. <i>Handbook of Experimental Pharmacology</i> , 1994 , 265-288	3.2	
6	Neue Befunde zur Kinetik trizyklischer Antidepressiva. 1994 , 17-28		
5	Prediction of Metabolite-to-Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model. <i>Clinical and Translational Science</i> , 2020 , 13, 520-528	4.9	0
4	Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. <i>Journal of Psychiatry and Neuroscience</i> , 1994 , 19, 30-44	4.5	14

- 3 The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study. *British Journal of Clinical Pharmacology*, **1993**, 35, 331-4 3.8 19
- 2 Recognition of functional genetic polymorphism using ESE motif definition: a conservative evolutionary approach to CYP2D6/CYP2C19 gene variants.
- 1 Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes. **2022**, 14, 2833 0